Clark Hill Advises HCW Biologics in $4.0 Million PIPE Offering
Featured
James Groth , Jeny Zarmon
Clark Hill’s Capital Markets team, led by Jim Groth and Jeny Zarmon, served as issuer’s counsel to HCW Biologics Inc. (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat chronic inflammation and age-related diseases, in connection with its $4.0 million private investment in public equity (PIPE) offering.
The financing consisted of shares of common stock and pre-funded warrants, together with accompanying common warrants. Clark Hill advised the company throughout the transaction, including securities law compliance, transaction structuring, offering documentation, and closing matters.
Additional details regarding the transaction were announced in the company’s press release and disclosed in the related SEC filing.
Clark Hill’s Capital Markets and Securities group is pleased to be part of the HCWB team on its mission to improve quality of life and extend healthy lifespan through breakthrough immunotherapies.
Subscribe for the latest
Subscribe